| Literature DB >> 32521293 |
Benedikt C Westphalen1, Carsten Bokemeyer2, Reinhard Büttner3, Stefan Fröhling4, Verena I Gaidzik5, Hanno Glimm6, Ulrich T Hacker7, Volker Heinemann8, Anna L Illert9, Ulrich Keilholz10, Thomas Kindler11, Martin Kirschner12, Bastian Schilling13, Jens T Siveke14, Thomas Schroeder15, Verena Tischler16, Sebastian Wagner17, Wilko Weichert18, Daniel Zips19, Sonja Loges20.
Abstract
Precision cancer medicine (PCM) holds great promises to offer more effective therapies to patients based on molecular profiling of their individual tumours. Although the PCM approach seems intuitive, multiple conceptional and structural challenges interfere with the broad implementation of PCM into clinical practice. Accordingly, concerted national and international efforts are needed to guide the further development and broad adoption of PCM in Germany. With support of the 'German Cancer Aid' (Deutsche Krebshilfe [DKH]) a task force 'Molecular Diagnostics and Therapy' was implemented. In two workshops supported by the DKH, delegates from the fourteen comprehensive cancer centresidentified key topics essential to implement quality-guided, harmonized and adaptable PCM. Based on an online questionnaire and using a modified Delphi approach, nine statements were drafted and evaluated within the group. These statements could serve as a basis to define a collaborative strategy for PCM in the future with the aim to sustain and further improve its quality.Entities:
Keywords: Genomic profiling; Molecular diagnostics; Molecular tumour board; Precision medicine; Precision oncology
Mesh:
Substances:
Year: 2020 PMID: 32521293 DOI: 10.1016/j.ejca.2020.04.019
Source DB: PubMed Journal: Eur J Cancer ISSN: 0959-8049 Impact factor: 9.162